Literature DB >> 6975675

Rosette-increasing factor (RIF) generated in vivo following PHA skin test.

M Kubota, H Mikawa.   

Abstract

In phytohaemagglutinin (PHA) skin test-positive individuals, rosette-increasing factor (RIF), which augmented active E and EA rosette formation, appeared in the serum following the PHA skin testing. This factor was detectable 6 hr after the application of PHA and reached a peak at 14 hr. The appearance of the factor was closely related to the delayed cutaneous hypersensitivity. When mononuclear (MN) cells derived from individuals exhibiting delayed cutaneous reaction were further cultured without the addition of PHA, a similar property was found in the supernatants. Fractionation of the cells by E rosetting revealed this factor to be the product of T lymphocytes. Moreover, despite a lower percentage in contaminated T lymphocytes, a higher RIF activity was observed in the supernatants of the nylon-wool-retained population. The production of RIF was completely inhibited by cytochalasin B, but was not affected by colchicine. Experiments utilizing cycloheximide revealed that new protein synthesis was only necessary for early activation steps. RIF is a kind of lymphokine synthesized in the active immune process in vivo. Therefore, to assay RIF in vivo may provide a new method for investigating the cellular immune competence of the given patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975675      PMCID: PMC1537358     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Rosette-formation with mouse erythrocytes. II. A marker for human B and non-T lymphocytes.

Authors:  S Gupta; R A Good; F P Siegal
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

2.  The active E rosette test: correlation with delayed cutaneous hypersensitivity.

Authors:  P J Felsburg; R Edelman; R H Bilman
Journal:  J Immunol       Date:  1976-04       Impact factor: 5.422

3.  Migration inhibitory activity in serum and cell supernatants in patients with Sezary syndrome.

Authors:  T Yoshida; R Edelson; S Cohen; I Green
Journal:  J Immunol       Date:  1975-03       Impact factor: 5.422

4.  Drugs which disrupt microtubules do not inhibit the initiation of lymphocyte activation.

Authors:  K Resch; D Bouillon; D Gemsa; R Averdunk
Journal:  Nature       Date:  1977-01-27       Impact factor: 49.962

5.  In vitro augmentation of lymphocyte sheep cell rosette formation by leukocyte dialysates.

Authors:  R S Holzman; H S Lawrence
Journal:  J Immunol       Date:  1977-05       Impact factor: 5.422

6.  Serum migration-inhibitory activity in patients with lymphoproliferative diseases.

Authors:  S Cohen; B Fisher; T Yoshida; R E Bettigole
Journal:  N Engl J Med       Date:  1974-04-18       Impact factor: 91.245

7.  The formation of stable E rosettes after neuraminidase treatment of either human peripheral blood lymphocytes or of sheep red blood cells.

Authors:  U Galili; M Schlesinger
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

8.  Temporal dependence of the inhibition by cytochalasin B of antigen-initiated migration inhibition factor production.

Authors:  S Z Sasson; A S Rosenthal
Journal:  J Immunol       Date:  1975-10       Impact factor: 5.422

9.  Levamisole increases activated T lymphocytes.

Authors:  M Rosenthal
Journal:  Lancet       Date:  1977-09-24       Impact factor: 79.321

10.  A simple rosette assay for demonstration of complement receptor sites using complement-coated zymosan beads.

Authors:  Ch Huber; H Wigzell
Journal:  Eur J Immunol       Date:  1976-06       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.